Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD
M. Cazzola, F. Calderaro, F. Di Perna, C. Califano, M. D'Amato, M. G. Matera, G. D'Amato (Naples, Italy)
Source: Annual Congress 2001 - Long-acting β2-agonists: clinical effects
Session: Long-acting β2-agonists: clinical effects
Session type: Oral Presentation
Number: 3471
Disease area: Airway diseases
Abstract The most effective dosage of β2-agonists may increase above that recommended during acute exacerbations of COPD. In this study, we compared the acute effects of higher than customary doses of SM and SB in 19 patients with acute exacerbation of COPD. A dose-response curve to SM pMDI, 25 μg/puff, or SB pMDI, 100 μg/puff, was constructed using 1puff, 1puff, and 2 puffs, i.e., a total cumulative dose of 100 μg SM or 400 μg SB on two consecutive days. After baseline measurements, dose increments were given at 30-minute intervals with measurements being made 25 minutes after each dose. Heart rate (HR) and pulse-oximetry (SpO2) measurements were then taken. Both SM and SB induced a large and significant (p<0.001) dose-dependent increase in FEV1 [mean differences from baseline (L) = after 100 μg SM: 0.174 (95% CI: 0.112–0.237); after 400 μg SB: 0.165 (95% CI: 0.080–0.249)] and in IC [mean differences from baseline (L) = after 100 μg SM: 0.328 (95% CI: 0.152-0.505); after 400 μg SB: 0.308 (95% CI: 0.133-0.483)]. There was no significant difference between the FEV1 values (p=0.418), and the IC values (p=0.585) after 100 μg SM and 400 μg SB. Also HR [mean differences from baseline (b/min) = after 100 μg SM: 3.16 (95% CI: -0.87-8.18); after 400 μg SB: 2.42 (95% CI: -0-97-5.81)] and SpO2 [mean differences from baseline (%) = after 100 μg SM: -0.21 (95% CI: -1.05-0.63); after 400 μg SB: -0.10 (95% CI: -1.00-0.79)] did not change significantly from baseline (p>0.05). These data indicate that SM is effective and safe in the treatment of acute exacerbation of COPD and support its use in this clinical condition.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Cazzola, F. Calderaro, F. Di Perna, C. Califano, M. D'Amato, M. G. Matera, G. D'Amato (Naples, Italy). Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD. Eur Respir J 2001; 16: Suppl. 31, 3471
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Comparison of the acute effects of formoterol (F) and formoterol/budesonide combination (FBC) on blood-gas tensions in patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003
Formoterol (Modulite), tiotropium and their combination in patients with acute exacerbation of chronic bronchitis: preliminary data Source: Eur Respir J 2005; 26: Suppl. 49, 285s Year: 2005
Acute asthma treatment: comparison of formoterol and salbutamol given in cumulative doses in children Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001
Relation between the acute response to salbutamol and long-term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T+F) in COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Formoterol (aerolizer) in acute asthma exacerbation Source: Eur Respir J 2002; 20: Suppl. 38, 52s Year: 2002
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
A comparison of salmeterol xinafoate (SX) plus beclomethasone dipropionate (BDP) and theophylline (Theo) plus BDP in the treatment of moderate chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018
A comparison of salmeterol xinafoate (SX) plus fluticasone propionate (FP) and slow-release theophylline (Theo) plus FP in the treatment of stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006
Addition of tiotropium (T) to a regular treatment with long-acting β-agonist+inhaled corticosteroid (LABA+ICS) in patients with severe to very-severe COPD under in-patient pulmonary rehabilitation program (PRP) Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease Year: 2009
Effect of fluticasone furoate (FF)/vilanterol (VI) compared with VI on acute exacerbations of COPD (AECOPD): A post-hoc analysis by baseline airflow obstruction Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Safety of formoterol Turbuhaler(R) at cumulative dose of 90 {micro}g in patients with acute bronchial obstruction Source: Eur Respir J 2001; 18: 928-934 Year: 2001
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Effect of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Formoterol/budesonide (FBC) in the treatment of acute exacerbation of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 288s Year: 2003
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013